Akanda

Akanda Equity Growth

The Year-over-Year Equity Growth of Akanda (AKAN) as of Nov 6, 2026 is -352.19 %. In the previous year, Year-over-Year Equity Growth was 211.69 % — a change of -266.37% (lower).

Equity Growth

-352.19 %

YoY

-266.37%

Last updated:

Year-over-Year Equity Growth of Akanda is 2025 -352.19 % . Year-over-Year Equity Growth of Akanda was 2024 211.69 % . It decreases by -266.37% lower compared to the previous year.

The Akanda Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2021
56.25 USD
Jan 1, 2022
1,321.94 USD
Jan 1, 2023
-114.23 USD
Jan 1, 2024
211.69 USD
Jan 1, 2025
-352.19 USD
The Akanda Equity Growth history
YEAREquity GrowthYoY
-352.19 %-266.37%
211.69 %-285.31%
-114.23 %-108.64%
1,321.94 %+2,250.08%
56.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Year-over-Year Equity Growth of Akanda is -352.19 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Akanda since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Akanda historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Akanda

All Key Metrics — Akanda